Physician

Lindsay Jo Orris, D.O.

According to 2025 Medicare claims, Lindsay Orris, D.O. (NPI: 1225263833) practices rheumatology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Scott, IA. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES, PC (NPI: 1851578868; TIN: 261643846) and primary practice location at 52722-1624. Orris is affiliated with the IRCCO (ACO ID: A2619), Genesis Accountable Care Organization, LLC. (ACO ID: A4799), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Orris' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 546 traditional Medicare patients, billed 113,917 HCPCS/CPT codes, and received $1,535,598 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,105 prescription claims across 613 beneficiaries totaling $3,442,134 in drug costs, led by Rinvoq (Upadacitinib). Open Payments data shows 37 records totaling $864. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $298,293 to $1,535,598. Similarly, Part D prescription costs have moved sharply higher in recent years, from $100,776 to $3,442,134. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	321	16,626	$298,293
2016	390	25,555	$575,376
2017	386	22,477	$498,890
2018	388	29,380	$604,457
2019	401	46,782	$790,307
2020	344	63,990	$846,941
2021	390	49,719	$781,216
2022	410	44,130	$680,154
2023	481	70,198	$959,798
2024	546	113,917	$1,535,598

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	1,032	$100,776
2016	220	1,555	$154,479
2017	233	1,532	$217,014
2018	271	1,777	$222,874
2019	331	2,500	$531,747
2020	360	2,775	$758,650
2021	432	3,076	$917,848
2022	449	3,235	$1,012,592
2023	500	3,472	$1,781,484
2024	613	4,105	$3,442,134

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	326	632	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	145	168	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	282	471	$12
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	202	331	$8
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	232	355	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	77	2,310	$514,818
Enbrel Mini	Etanercept	49	1,428	$385,723
Orencia Clickject	Abatacept	62	1,736	$371,098
Enbrel	Etanercept	38	1,064	$275,930
Taltz Autoinjector	Ixekizumab	26	728	$255,784

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	37	$864	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lindsay Jo Orris, D.O.?

Tedicare shows public-source Medicare data for Lindsay Jo Orris, D.O. (NPI 1225263833), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lindsay Jo Orris, D.O. have ACO affiliation data?

Lindsay Jo Orris, D.O. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Lindsay Jo Orris, D.O.?

Lindsay Jo Orris, D.O. is linked to RHEUMATOLOGY ASSOCIATES, PC (billing NPI 1851578868) in the available physician profile data.

Does Lindsay Jo Orris, D.O. have Open Payments data?

Lindsay Jo Orris, D.O. has 37 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.